BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

EDAP TMS (EDAPY) Announces A Letter Of Intent With HealthTronics Surgical Services, Inc. (HTRN) On Ablatherm(R) In The U.S.A.


10/19/2005 5:09:31 PM

VAULX-EN-VELIN, France, Dec. 15 /PRNewswire-FirstCall/ -- EDAP TMS S.A. , a global leader in the development, marketing and distribution of a portfolio of minimally-invasive medical devices for the treatment of urological diseases, today announced that it has entered into a letter of intent with HealthTronics Surgical Services, Inc. ("HealthTronics") . This letter of intent outlines terms that would grant HealthTronics the right to begin clinical trials with the Ablatherm, a medical device that utilizes High Intensity Focused Ultrasound ("HIFU") to provide minimally invasive treatment of prostate cancer, to obtain Pre-Market Approval ("PMA") from the Food and Drug Administration ("FDA") and would grant HealthTronics exclusive distribution rights in the United States, when and if, a PMA is granted by the FDA. The letter of intent is subject to the negotiation and execution of definitive agreements between EDAP TMS and HealthTronics.

The final agreement between the two companies will include the issuance of warrants by EDAP TMS S.A. to HeathTronics in consideration for providing services related to pursuing a PMA from the FDA. Certain aspects of the proposed transaction will require the approval of the shareholders of EDAP TMS at an extraordinary shareholder meeting prior to the execution of a final agreement. The Board of Directors anticipates calling such a meeting to be held at the end of January 2004. Shareholders of EDAP TMS S.A. will receive details of the resolutions to be voted on as soon as the Board has finalized the meeting and record dates.

Philippe Chauveau, Chairman and Chief Executive Officer of EDAP TMS S.A. commented, "We are pleased to announce that we are moving forward with a partnership in the United States for our HIFU technology. We look forward to discussing this partnership with our shareholders as we progress towards the shareholders meeting at the end of January, 2004." Argil J. Wheelock, M.D., Chairman and Chief Executive Officer of HealthTronics Surgical Services, Inc. commented, "We are very pleased to have reached preliminary terms with EDAP and look forward to finalizing a definitive agreement and moving forward with the project."

EDAP TMS S.A. is the global leader in the development, production, marketing and distribution of a portfolio of minimally invasive medical devices primarily for the treatment of urological diseases. The Company currently produces and markets devices for the minimally invasive treatment of localized prostate cancer, using High Intensity Focused Ultrasound (HIFU) and the treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). The Company also produces and markets in Japan and Italy devices for the non-surgical treatment of benign Prostate Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). The Company is also developing HIFU for the treatment of certain other types of tumors. For more information, in the U.S., contact EDAP Technomed Inc., the Company's U.S. subsidiary located in Atlanta, GA, by phone at (770) 446-9950. For additional information on the Company, please see the Company's web site at: http://www.edaptechnomed.com/.

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.

CONTACT: Philippe Chauveau / Blandine Confort 33.4.72.15.31.50 Ian Vawter - EDAP Technomed Inc. 1.770.446.9950

EDAP TMS S.A.

CONTACT: Philippe Chauveau or Blandine Confort, +33-4-72-15-31-50, orIan Vawter of EDAP Technomed Inc., +1-770-446-9950


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->